Volberding P A
Semin Oncol. 1987 Jun;14(2 Suppl 3):23-6.
Studies of classic, and especially African, Kaposi's sarcoma in the 1970s showed that both forms of the disease respond to cytotoxic chemotherapy. The agents that had proven effective against these forms of neoplasm were among the first to be tried for managing epidemic Kaposi's sarcoma (EKS). Thus far, single-agent regimens using either vinblastine, vincristine, or etoposide have apparently shown the greatest efficacy in AIDS-associated Kaposi's sarcoma, with overall response rates of up to nearly 90% in some trials. Various combination regimens have been studied with a view to reducing side effects, particularly immune suppression, while maintaining overall efficacy. Thus far, only an alternating regimen of vinblastine and vincristine shows promise. Despite intrinsic shortcomings, chemotherapy, using cytotoxics alone or in combination with biologic response modifiers and other modalities, will play a role in managing EKS, even as the search for the optimal regimen continues.
20世纪70年代对经典型，尤其是非洲型卡波西肉瘤的研究表明，这两种形式的疾病对细胞毒性化疗均有反应。已被证明对这些肿瘤形式有效的药物是最早用于治疗流行性卡波西肉瘤（EKS）的药物之一。迄今为止，使用长春碱、长春新碱或依托泊苷的单药方案在艾滋病相关卡波西肉瘤中显然显示出最大疗效，在一些试验中总体缓解率高达近90%。为了在保持总体疗效的同时减少副作用，特别是免疫抑制，人们研究了各种联合方案。迄今为止，只有长春碱和长春新碱交替方案显示出前景。尽管存在固有缺点，但化疗，无论是单独使用细胞毒性药物还是与生物反应调节剂及其他方式联合使用，在治疗EKS中都将发挥作用，即使对最佳方案的探索仍在继续。
